Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1330

3.

p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.

Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK.

Cancer Res. 2003 Nov 1;63(21):7081-8.

4.

Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.

Yang X, Xing H, Gao Q, Chen G, Lu Y, Wang S, Ma D.

Gynecol Oncol. 2005 May;97(2):413-21.

PMID:
15863139
5.

Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.

Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T, Murata Y.

Cancer Res. 2000 Nov 1;60(21):5988-94.

6.

Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway.

Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M, Tsang BK.

Drug Resist Updat. 2002 Jul-Aug;5(3-4):131-46. Review.

PMID:
12237081
7.
8.
9.
10.

Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.

Henkels KM, Turchi JJ.

Cancer Res. 1999 Jul 1;59(13):3077-83. Erratum in: Cancer Res 2000 Feb 15;60(4):1150.

11.

The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.

Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR.

Cancer Res. 2000 Oct 1;60(19):5390-4.

12.

AKT involvement in cisplatin chemoresistance of human uterine cancer cells.

Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E.

Gynecol Oncol. 2004 Sep;94(3):785-95.

PMID:
15350374
13.
14.

Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt.

Yang X, Fraser M, Abedini MR, Bai T, Tsang BK.

Br J Cancer. 2008 Feb 26;98(4):803-8. doi: 10.1038/sj.bjc.6604223.

15.

Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.

Kolfschoten GM, Hulscher TM, Schrier SM, van Houten VM, Pinedo HM, Boven E.

Gynecol Oncol. 2002 Mar;84(3):404-12.

PMID:
11855878
16.

Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol.

Gagnon V, Van Themsche C, Turner S, Leblanc V, Asselin E.

Apoptosis. 2008 Feb;13(2):259-71.

PMID:
18071906
17.

[Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].

Wang Y, Li LZ, Ye L, Niu XL, Liu X, Zhu YQ, Sun WJ, Liang YJ.

Zhonghua Fu Chan Ke Za Zhi. 2010 Sep;45(9):691-8. Chinese.

PMID:
21092551
18.

Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.

Wang Y, Mao H, Hao Q, Wang Y, Yang Y, Shen L, Huang S, Liu P.

Regul Pept. 2012 Oct 10;178(1-3):36-42. doi: 10.1016/j.regpep.2012.06.005.

PMID:
22759793
19.
20.

alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.

Yu W, Shun MC, Anderson K, Chen H, Sanders BG, Kline K.

Apoptosis. 2006 Oct;11(10):1813-23.

PMID:
16850165
Items per page

Supplemental Content

Support Center